Flexibility to help you meet your patients’ needs1


AJOVY is the only approved anti-CGRP treatment for the prevention of migraine with quarterly and monthly dosing options


675 mg (225 mg x 3) SQ

Only 4 injection days per year



225 mg SQ

Only 1 injection per month


In office

by a healthcare professional


At home

by a patient or caregiver

Guidance on proper subcutaneous administration techniques should be provided.


Alone and in combination with oral preventive treatments

  • 1000+ patients received AJOVY as a stand-alone preventive treatment
  • 280+ patients continued to receive their oral preventive treatment


Real-world patients

  • Phase 3 trials enrolled nearly 600 patients that had discontinued prior preventive treatment2

  • 18% of women of childbearing age also took concomitant oral hormonal contraceptives2

There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life. This should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY.1


CGRP: calcitonin gene-related peptide; SQ: subcutaneous.

Suggestions to explore next

AJOVY helped significantly reduce monthly migraine days vs placebo1

see the clinical trial data for ajovy

Savings Offer for AJOVY

Download Savings Offer

AJOVY is a monoclonal antibody that selectively targets the CGRP ligand1

see how ajovy works